Committed to Neurovascular Excellence: The Evolution of Stryker’s Stent Innovation and Leadership
The Stryker symposium took place on the first day of
LINNC Paris 2019
and offered the opportunity for interventional neuroradiologists from around the world to share insights on the latest aneurysm’s treatment platforms developed by Stryker through their ongoing - and historic - commitment to neurovascular therapies.
The symposium began with Dr. Brian Jankowitz, Co-Director of Endovascular Therapy and Director of the Neuroendovascular Fellowship Program of the University of Pittsburgh, Pittsburgh, PA, USA presenting his experience in using the Neuroform Atlas Stent. Calling it a “dramatic evolution”, Dr Jankowitz declared that “it has completely changed the way I think about treating aneurysms”. Describing it as easy to use and deploy, Dr Jankowitz appreciates that the design of the Neuroform Atlas Stent System allows for accuracy in the landing zone. The stent has excellent radial force and as soon as the end “flowers and touches the vessel wall, it is anchored in place and will not slide, either proximally or distally".
In Europe, where many other types of stents are available in the interventional endovascular armamentarium, the Neuroform Atlas Stent is proving to be safe and effective. In the US, Neuroform Atlas recently received Pre-Market Approval (PMA) based on the strong results of the US Atlas IDE study which showed an impressive 84,7% Raymond I occlusion rate at 12 months. Dr. Jankowitz commented that these results are comparable to the occlusion rates found in the landmark ISAT trial.
The design of Neuroform offers a reduced metallic surface versus competitors. As Brian Jankowitz explained, when you have chosen to use a stent and not to flow divert, you want a stent that will leave “the least metal behind” and with the Neuroform Atlas Stent System he has found his “optimal” tool.
New frontiers in flow diversion
The symposium then turned to the latest data now emerging from the early experience with the new Surpass Evolve Flow Diverter. Prof. Timo Krings from the UHN Division of Neuroradiology, University of Toronto, Toronto, Canada presented his group’s initial impressions of this new flow diverter, discussing soon to be published data from the first five patients. With excellent results – Surpass Evolve incorporates the benefits of the previous version, Surpass Streamline, with improved procedural ease of use, excellent pushability and a stable distal landing zone. Furthermore, Surpass Evolve has demonstrated that it opens well and does not twist when placed.
Then, Prof. Vincent Costalat from the Department of Neuroradiology, Gui de Chauliac University Hospital, Montpellier, France shared the early European experience with the Surpass Evolve Flow Diverter. He described the design of this innovative device, which leverages a higher braid angle compared to the previous version, offering improved vessel wall apposition and the same level of flow diversion despite having fewer wires. Prof. Costalat characterized the difference between Surpass Evolve and Surpass Streamline as a complete paradigm shift – evolving from an over-the-wire delivery to an empty catheter which provides enhanced trackability.
We are now waiting for follow-up from the more than 75 patients who have already been successfully treated worldwide with the device. According to both Prof. Krings and Costalat, Surpass Evolve is a highly optimized device that promises to be an excellent new tool in the treatment of patients with brain aneurysms.
All in all, Stryker remains at the forefront of stent design and innovation and continues to point the way to the future of interventional neuroradiology and neurosurgery, building on decades of experience, physician partnership and trust.